FDA names Mary Thanh Hai as permanent director of Office of New Drugsnews2025-10-27T15:48:22+00:00October 27th, 2025|Endpoints News|
FDA approves Syndax’s menin inhibitor with black-box warning; GSK’s ADC dealnews2025-10-27T15:13:54+00:00October 27th, 2025|Endpoints News|
Zenas’ multiple sclerosis drug slows new brain lesions in mid-stage trialnews2025-10-27T15:00:40+00:00October 27th, 2025|Endpoints News|
Novartis CEO says $12B Avidity deal could have been ‘twice as big’news2025-10-27T14:57:51+00:00October 27th, 2025|Endpoints News|
Takeaways from Endpoints AI Day: Real progress, ‘stupid’ money and moonshotsnews2025-10-27T14:00:29+00:00October 27th, 2025|Endpoints News|
WuXi AppTec to divest clinical services to focus on manufacturing businessnews2025-10-27T13:42:32+00:00October 27th, 2025|Endpoints News|
MicroRNA startup Causeway targets raise after results of tendinopathy studynews2025-10-27T13:00:06+00:00October 27th, 2025|Endpoints News|
BridgeBio shifts filing plans for rare disease drug after Phase 3 successnews2025-10-27T11:00:42+00:00October 27th, 2025|Endpoints News|
Neumora moves forward with NLRP3 in obesity after Ventyx’s drug failed to deliver weight lossnews2025-10-27T10:30:05+00:00October 27th, 2025|Endpoints News|
Hemab nabs $157M to finance the ‘ultimate coagulation disorder’ biotechnews2025-10-27T10:00:58+00:00October 27th, 2025|Endpoints News|
